Previous 10 | Next 10 |
Bellicum Pharmaceuticals (NASDAQ: BLCM ) has priced its public offering of 575K shares of Series 1 preferred stock and seven-year warrants to purchase up to 57.5M common shares (100 shares/warrant) at $1 per share and accompanying warrant. Gross proceeds should be ~$57.5M (not sure of its ...
HOUSTON, Aug. 16, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the pricing of an underwritten public offering of 575,000 shares of...
Bellicum Pharmaceuticals (NASDAQ: BLCM ) is offering to sell shares of its Series 1 preferred stock and warrants to purchase common shares in a public offering for gross proceeds of ~$53M. More news on: Bellicum Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
HOUSTON, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that it is offering to sell, subject to market and other conditions...
Bellicum Pharmaceuticals (NASDAQ: BLCM ): Q2 GAAP EPS of -$0.58 misses by $0.04 . More news on: Bellicum Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Interim safety and activity data for BPX-601 presented at American Society of Clinical Oncology (ASCO) Annual Meeting Rivo-cel TM achieved primary endpoint in BP-004 European registrational trial HOUSTON, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (N...
Bellicum Pharmaceuticals ( BLCM ) announced that the Rivo-cel hit its primary endpoint in its BP-004 European registration trial of event-free survival at 180 days. The BP-004 data will be the basis for the company’s European MAAs submission for Rivo-cel and rimiducid which could lead...
KalVista Pharmaceuticals (NASDAQ: KALV ) initiated with Outperform rating and $31 (83% upside) price target at SVB Leerink. More news on: KalVista Pharmaceuticals, Inc., Gilead Sciences, Inc., Galapagos NV, Healthcare stocks news, Stocks on the move, , Read more ...
Nano cap Bellicum Pharmaceuticals ( BLCM +2.8% ) perks up on below-average volume in response to positive results from a European registration trial supporting its Rivo-cel (rivogenlecleucel) allogeneic T cell product in pediatric patients with malignant or non-malignant blood cell dis...
Oasmia Pharmaceutical AB (NASDAQ: OASM ) +22% . More news on: Oasmia Pharmaceutical AB (publ), Sangamo Therapeutics, Inc., Aytu BioScience, Inc., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Bellicum Pharmaceuticals Inc. Company Name:
BLCM Stock Symbol:
NASDAQ Market:
Bellicum Pharmaceuticals Inc. Website:
Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
Kajima Corporation ADR (KAJMY) is expected to report for quarter end 2023-12-31 FaZe Holdings Inc. (FAZE) is expected to report for Q4 2023 BrewBilt MFG Inc (BBRW) is expected to report for Q4 2023 Correlate Energy Corp. (CIPI) is expected to report for Q4 2023 Hyzon Motors Inc. (...